Achieving clinical response in postpartum depression leads to improvement in health-related quality of life.

Postpartum depression SF-36v2 Health Survey health-related quality of life healthcare resource utilization productivity

Journal

Current medical research and opinion
ISSN: 1473-4877
Titre abrégé: Curr Med Res Opin
Pays: England
ID NLM: 0351014

Informations de publication

Date de publication:
07 2021
Historique:
pubmed: 16 3 2021
medline: 16 10 2021
entrez: 15 3 2021
Statut: ppublish

Résumé

To evaluate the health-related quality of life (HRQoL) burden associated with postpartum depression (PPD), determine the extent to which clinical response impacts HRQoL, and estimate the impact of PPD and clinical response on healthcare resource utilization (HRU) and productivity. Patient data ( Baseline HRQoL of patients with PPD was significantly below normative values. Day 7 and day 30 clinical response were associated with large and statistically significant improvements in HRQoL, greater likelihood of meeting SF-36v2 responder definitions, and reduced impairment. MCS levels corresponding to those observed in clinical responders were linked to lower HRU and productivity loss relative to non-responders. PPD places a substantial burden on HRQoL. Achievement of rapid clinical response (at day 7) and clinical response sustained several weeks following the end of treatment (day 30) led to significant improvement in HRQoL, suggesting the importance of identifying women with PPD and providing effective treatment options.

Identifiants

pubmed: 33719782
doi: 10.1080/03007995.2021.1902295
doi:

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1221-1231

Auteurs

Margaret E Gerbasi (ME)

Sage Therapeutics, Inc., Cambridge, MA, USA.

Samantha Meltzer-Brody (S)

Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Sarah Acaster (S)

Acaster Lloyd Consulting Ltd., London, UK.

Moshe Fridman (M)

AMF Consulting, Los Angeles, CA, USA.

Ming-Yi Huang (MY)

Sage Therapeutics, Inc., Cambridge, MA, USA.

Vijayveer Bonthapally (V)

Sage Therapeutics, Inc., Cambridge, MA, USA.

Paul Hodgkins (P)

Sage Therapeutics, Inc., Cambridge, MA, USA.

Stephen J Kanes (SJ)

Sage Therapeutics, Inc., Cambridge, MA, USA.

Adi Eldar-Lissai (A)

Sage Therapeutics, Inc., Cambridge, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH